Phase Genomics is a life science innovation company that develops ultra-long-range genome sequencing technology and computational tools for genomics, cytogenetics, oncology, and microbiology. The company's proprietary Proximo Hi-C and ProxiMeta platforms use proximity ligation to measure the physical proximity of DNA in vivo, enabling scientists to scaffold contigs into entire chromosomes, deconvolute complex metagenomic samples, reconstruct viral genomes, attribute mobile genetic elements to their hosts, and construct high-quality chromosome-scale reference genomes. These capabilities address critical challenges in cancer research, infectious disease surveillance, antibiotic resistance tracking, and plant and animal genomics. Founded in 2015 and headquartered in Seattle, Washington, Phase Genomics has raised approximately $5.8 million in Series A funding from investors including NHGRI, NIH, NIAID, the Gates Foundation, Congruent Ventures, Washington Research Foundation, and the National Cancer Institute.
Phase Genomics
Series APhase Genomics is a life science innovation company that develops ultra-long-range genome sequencing technology and computational tools for genomics, cytogenetics, oncology, and microbiology. The company's proprietary Proximo Hi-C and ProxiMeta platforms use proximity ligation to measure the physical proximity of DNA in vivo, enabling scientists to scaffold contigs into entire chromosomes, deconvolute complex…
About
Business model
Genomics > Enabling Technologies > Technology Platforms > Gene Delivery,
Life Sciences Platforms and Tools > Research Services > Genomics > Next Generation Sequencing (NGS)
Team background
Company Wise > Microsoft,
College Wise > Massachusetts Institute of Technology, Cornell University
Institutional investors
Latest coverage
📰 Browse funding news — rounds, valuations, and market moves for founders.
Investor directory
🗂️ Explore Life Sciences investors — funds that write checks in this sector.